Use of β-blockers and β-agonists in COPD: A review of clinical outcomes

Respiratory Medicine: COPD Update

Volumn 2, Issue 4, 2007, Pages 133-139

  Salpeter, Shelley R ^a,b   Buckley, Nicholas S ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c International Baccalaureate Program   (United States)

Author keywords

Beta adrenergic agonist; Beta adrenergic blocker; Chronic obstructive pulmonary disease; COPD; Meta analysis; Systematic review

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; SALBUTAMOL; SALMETEROL;

ARTICLE; ASTHMA; BETA ADRENERGIC STIMULATION; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; DISEASE CONTROL; DRUG MECHANISM; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HEART ARREST; HEART DEATH; HEART DISEASE; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 33846579969     PISSN: 17450454     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmedu.2006.11.001     Document Type: Article

References (30)

1. Bristow M.R. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 101 5 (2000) 558-569
2. Ablad B., Carlsson E., Dahlof C., and Ek L. Some aspects of the pharmacology of beta-adrenorecptor blockers. Drugs 11 Suppl 1 (1976) 100-111
3. Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med 158 5 Pt 3 (1998) S146-S153
4. Brophy J.M., Joseph L., and Rouleau J.L. Beta-blockers in congestive heart failure. Ann Intern Med 134 (2001) 550-560
5. Prichard B.N., and Gillam P.M. Treatment of hypertension with propranolol. Br Med J 1 635 (1969) 7-16
6. Auerbach A.D., and Goldman L. Beta-blockers and reduction of cardiac events in noncardiac surgery: clinical applications. J Am Med Assoc 287 11 (2002) 1445-1447
7. Freemantle N., Cleland J., Young P., Mason J., and Harrison J. β-Blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 318 7200 (1999) 1730-1737
8. Yusuf S., Peto R., Lewis J., Collins R., and Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 5 (1985) 335-371
9. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 UK Prospective Diabetes Study Group. Br Med J 317 7160 (1998) 713-720
10. Frishman W., Silverman R., Strom J., Elkayam U., and Sonnenblick E. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a beta-adrenoreceptor blocker. Am Heart J 98 2 (1979) 256-262
11. Salpeter S., Ormiston T., and Salpeter E. Cardioselective beta-blocker use in patients with reactive airway disease: a meta-analysis. Ann Intern Med 137 (2002) 715-725
12. Salpeter S.R., Ormiston T.M., Salpeter E.E., Poole P.J., and Cates C.J. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 97 10 (2003) 1094-1101
13. Salpeter S.R., Ormiston T.M., and Salpeter E.E. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 140 10 (2004) 802-813
14. Spitzer W.O., Suissa S., Ernst P., et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326 8 (1992) 501-506
15. Lanes S.F., Garcia Rodriguez L.A., and Huerta C. Respiratory medications and risk of asthma death. Thorax 57 (2002) 683-686
16. Au D.H., Curtis J.R., Every N.R., McDonell M.B., and Fihn S.D. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest 121 3 (2002) 846-851
17. Au D.H., Lemaitre R.N., Curtis J.R., Smith N.L., and Psaty B.M. The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med 161 3 Pt 1 (2000) 827-830
18. Coughlin S.S., Metayer C., McCarthy E.P., et al. Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy. The Washington, DC, Dilated Cardiomyopathy Study. Am J Epidemiol 142 4 (1995) 395-403
19. Lemaitre R.N., Siscovick D.S., Psaty B.M., et al. Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest. Am J Med 113 9 (2002) 711-716
20. Martin R.M., Dunn N.R., Freemantle S.N., and Mann R.D. Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists. Thorax 53 7 (1998) 558-562
21. Sengstock D.M., Obeidat O., Pasnoori V., Mehra P., Sandberg K.R., and McCullough P.A. Asthma, beta-agonists, and development of congestive heart failure: results of the ABCHF study. J Card Fail 8 4 (2002) 232-238
22. Suissa S., Hemmelgarn B., Blais L., and Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 154 6 Pt 1 (1996) 1598-1602
23. Salpeter S.R., Ormiston T.M., and Salpeter E.E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 125 6 (2004) 2309-2321
24. Donohue J.F., Menjoge S., and Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 97 9 (2003) 1014-1020
25. van Schayck C.P., Graafsma S.J., Visch M.B., Dompeling E., van Weel C., and van Herwaarden C.L. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol 86 5 (1990) 793-800
26. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., and Dorinsky P.M. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 1 (2006) 15-26
27. Salpeter S.R., Buckley N.S., Ormiston T.M., and Salpeter E.E. Long-acting beta-agonists increase severe asthma exacerbations and asthma-related deaths: meta-analysis of randomized controlled trials. Ann Intern Med 144 (2006) 904-912
28. US Food and Drug Administration Advisory Committee. Serevent, Advair, Foradil withdrawals to be considered by Advisory Committee. Available at 〈http://www.fdaadvisorycommittee.com/FDC/AdvisoryCommittee/Committees/Pulmonary-Allergy%20Drugs/071305_betasafety/071305_BroncoP.htm. Accessed August 8, 2005〉.
29. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: Anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006;21: DOI:10.1111/j.1525-1497.2006.00507x.
30. Salpeter S.R., and Buckley N.S. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: β-agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol 31 (2006) 219-230